How should nitroglycerin (NTG) be used for acute chest pain relief and short‑term blood pressure control after coronary artery bypass grafting (CABG)?

Nitroglycerin Use After CABG

For acute chest pain relief after CABG, administer sublingual nitroglycerin 0.3-0.4 mg every 5 minutes for up to 3 doses; for persistent ischemia or hypertension requiring blood pressure control, initiate intravenous nitroglycerin at 10 mcg/min and titrate upward by 10 mcg/min every 3-5 minutes until symptom relief or blood pressure response, avoiding systolic BP <90 mmHg. 1, 2

Acute Chest Pain Management

Sublingual Administration

• Initial dose: 0.3-0.4 mg sublingual or spray 1, 2
• Timing: One dose at first sign of chest pain
• Repeat dosing: Every 5 minutes for maximum of 3 doses 1, 2
• Onset of action: 1-3 minutes, peak effect at 5 minutes 2
• Duration: Effects persist at least 25 minutes 2

When to Escalate to IV Therapy

If chest pain persists after 3 sublingual doses or if patient has ongoing ischemia, heart failure, or hypertension, transition to intravenous nitroglycerin 1.

Intravenous Nitroglycerin Protocol

Initiation and Titration

• Starting dose: 10 mcg/min via continuous infusion through non-absorbing tubing 3, 4, 5
• Titration schedule:
  • Increase by 10 mcg/min every 3-5 minutes until symptom relief or BP response 3, 4, 5
  • If no response at 20 mcg/min, use increments of 10-20 mcg/min 4, 5
  • Once partial BP response observed, reduce dosage increments and lengthen intervals 4, 5
• Maximum dose: Commonly 200 mcg/min, though doses up to 300-400 mcg/min have been used safely 3

Blood Pressure Targets and Contraindications

Critical safety parameters:

• Avoid if: Systolic BP <90 mmHg or >30 mmHg below baseline 3, 4, 5
• Target: Do not reduce systolic BP below 110 mmHg in normotensive patients 4, 5
• In hypertensive patients: Do not reduce mean arterial pressure by >25% from baseline 4, 5
• Contraindicated with: Recent phosphodiesterase inhibitor use (sildenafil within 24h, tadalafil/vardenafil within 48h) 4, 5

Duration and Conversion Strategy

Short-term Use (First 24 Hours)

• Tolerance develops after 7-8 hours of continuous IV infusion 3
• Tolerance becomes clinically important after 24 hours 3, 5
• If continued beyond 24 hours, periodic dose increases may be needed 3, 5

Transition to Non-parenteral Therapy

When to convert 3, 5:

• After patient is free of ischemic symptoms for 12-24 hours
• Generally within 24 hours of stabilization
• Do not continue IV NTG in patients free of ischemia signs/symptoms

Conversion options 3:

• Transdermal: 0.2-0.8 mg/h every 12 hours (provides nitrate-free interval)
• Oral isosorbide dinitrate: 5-80 mg 2-3 times daily
• Oral isosorbide mononitrate: 20 mg twice daily or 60-240 mg slow-release once daily

Discontinuation

• Gradual taper required: Abrupt cessation associated with rebound ischemic ECG changes 3
• Reduce dose gradually before stopping 3

Efficacy in CABG Context

Evidence Quality

The evidence for NTG in post-CABG patients is mixed:

• Historical data: Pre-fibrinolytic era studies suggested 35% mortality reduction 3
• Modern trials: ISIS-4 and GISSI-3 failed to confirm mortality benefit in reperfusion era 3
• Current rationale: Based on pathophysiological principles and uncontrolled clinical observations rather than randomized controlled trials 3

Specific CABG Studies

Research in CABG patients shows 6, 7, 8:

• Effective for: Pulmonary hypertension (86% success rate), myocardial ischemia (92% success), ventricular failure (87% success) 6
• Less effective for: Hypertension during cardiopulmonary bypass (60% success) 6
• Onset: 4-8 minutes in surgical setting 6
• Effective concentration: 1.7-2.9 mcg/kg/min 6

Important caveat: One study found prophylactic high-dose NTG (2 mcg/kg/min) did not reduce ischemia or infarction rates in accelerated recovery CABG protocols 9, suggesting therapeutic rather than prophylactic use is appropriate.

Common Pitfalls

1. Hypotension: Most common adverse effect; requires frequent BP monitoring, especially during titration 3, 4
2. Headache: Frequently reported but rarely requires discontinuation 3, 10
3. Tolerance: Develops predictably; use lowest effective dose and plan early conversion to intermittent dosing 3, 5
4. Drug interactions: Always verify no recent phosphodiesterase inhibitor use before administration 4, 5
5. Aortic stenosis: May cause marked hypotension; use with extreme caution 10